Price T Rowe Associates Inc Terns Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,694 shares of TERN stock, worth $140,926. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,694
Previous 18,433
12.27%
Holding current value
$140,926
Previous $120,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TERN
# of Institutions
118Shares Held
61MCall Options Held
155KPut Options Held
48.3K-
Orbimed Advisors LLC San Diego, CA7.62MShares$51.9 Million1.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.66MShares$45.3 Million5.84% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$41.5 Million1.32% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.43MShares$23.4 Million0.01% of portfolio
-
Vr Adviser, LLC New York, NY3.41MShares$23.2 Million1.92% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $256M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...